Skip to main content

Table 2 Comparisons of mutation types across clinical study groups. Only breast cancers with at least one variant were counted

From: Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses

Group

Mutation type

Mean

SD

Min

Max

Whole cohort

CNA

0.7

1.5

0

16

FUSION

0.1

0.4

0

4

INFRAME

0.0

0.2

0

2

MISSENSE

1.8

5.9

0

64

OTHER

0.5

4.4

0

64

TRUNCATION

0.2

1.1

0

16

Group 1A

CNA

0.5

0.7

0

3

FUSION

0.1

0.4

0

3

INFRAME

0.0

0.0

0

0

MISSENSE

1.1

1.0

0

4

OTHER

0.1

0.3

0

2

TRUNCATION

0.1

0.3

0

2

Group 1B

CNA

6.5*

7.6

0

16

FUSION

0.2

0.6

0

2

INFRAME

0.0

0.0

0

0

MISSENSE

9.8

18.9

0

48

OTHER

0.4

1.2

0

4

TRUNCATION

0.1

0.3

0

1

Group 2

CNA

0.5

0.6

0

2

FUSION

0.0

0.0

0

0

INFRAME

0.0

0.0

0

0

MISSENSE

7.7

17.1

0

64

OTHER

1.8

7.4

0

32

TRUNCATION

1.1

3.7

0

16

Group 3–1

CNA

0.9

0.9

0

3

FUSION

0.0

0.0

0

0

INFRAME

0.1

0.4

0

2

MISSENSE

0.5

0.7

0

2

OTHER

0.1

0.3

0

1

TRUNCATION

0.2

0.9

0

4

Group 3–2

CNA

0.6

0.5

0

1

FUSION

0.0

0.0

0

0

INFRAME

0.2

0.4

0

1

MISSENSE

0.6

0.9

0

2

OTHER

0.0

0.0

0

0

TRUNCATION

0.2

0.4

0

1

Retrospective cohort

CNA

0.6

0.5

0

1

FUSION

0.0

0.0

0

0

INFRAME

0.2

0.4

0

1

MISSENSE

0.6

0.9

0

2

OTHER

0.0

0.0

0

0

TRUNCATION

0.2

0.4

0

1

  1. *P < 0.01